This study advances the fundamental understanding of CoA and how it gets to where it needs to be in order to perform its essential functions. That, in turn, sheds light on how disruptions of this process might contribute to illness.
For instance, mutations in the genes that produce CoA transporters are associated with diseases such as encephalopmyopathy, a disorder that can include neurodevelopmental delay, epilepsy, and decreased muscle tone. Mutations in the enzymes that produce CoA have been implicated in neurodegeneration.
Going forward, Shen and her lab are investigating what role mitochondria CoA regulation plays in specialized cell types, such as neurons, and how dysregulation might contribute to disease.
“In the context of brain disorders, such as neurodegeneration and psychiatric disorders, there’s an emerging idea that dysregulated mitochondrial metabolism is a contributor,” says Shen, who notes that her interest in micronutrients like vitamin B5 is part of a long Yale history in the study of metabolism stretching back more than a century to Lafayette Mendel, PhD, former Sterling Professor of Physiological Chemistry whose discoveries included vitamin A and vitamin B complex in the mid-1910s.
“We hope to contribute to this legacy and with our deep understanding of cellular metabolism, we hope we can provide new directions for diagnosing and possibly treating these diseases down the road.”
The research reported in this news article was supported by the National Institutes of Health (award R35GM150619) and Yale University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support was provided by the 1907 Foundation, the Rita Allen Foundation, and the Klingenstein-Simons Fellowship.